Education
About Us
Working with TipRanks
Follow Us
Candel Therapeutics, Inc. (CADL)
NASDAQ:CADL
CADL Stock Chart & Stats
$5.10
$0.00(0.00%)
At close: 4:00 PM EST
$5.10
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$4.25 - $9.08
Previous CloseN/A
Volume524.53K
Average Volume (3M)1.17M
Market Cap
$373.56M
Enterprise Value$199.27M
Total Cash (Recent Filing)$86.96M
Total Debt (Recent Filing)$6.23M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
May 07, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding73,246,925
10 Day Avg. Volume1,509,362
30 Day Avg. Volume1,172,176
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)4.15
Price to Sales (P/S)0.00
P/FCF Ratio-10.17
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-214.96
Enterprise Value/Ebitda-9.61
Forecast
1Y Price Target
$15.00Price Target Upside194.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Physician UptakeRobust Phase 3 prostate cancer results and positive Phase 2 survival data in lung cancer, coupled with strong key opinion leader feedback, bolster confidence in clinical benefit and could accelerate physician adoption.
Manufacturing And Supply ReadinessScaled manufacturing with established viral and cell banks plus ongoing process performance qualification runs addresses commercial supply concerns and supports a smoother BLA review.
Regulatory PathwayFDA alignment on comparability analysis for CAN-2409 reduces the likelihood of requests for additional clinical or preclinical studies, lowering a critical hurdle for BLA submission and approval prospects.
Bears Say
Cardiovascular Safety Concerns Tied To ADTElevated cardiovascular risk associated with androgen deprivation therapy may complicate treatment decision making and regulatory scrutiny, potentially affecting how new prostate cancer therapies are positioned and adopted.
Financing And Dilution RiskReliance on external financing despite a debt deal with Trinity Capital signals a potential need for additional capital, increasing the risk of future share dilution or program delays.
Candel Therapeutics News
CADL FAQ
What was Candel Therapeutics, Inc.’s price range in the past 12 months?
Candel Therapeutics, Inc. lowest stock price was $4.25 and its highest was $9.08 in the past 12 months.
What is Candel Therapeutics, Inc.’s market cap?
Candel Therapeutics, Inc.’s market cap is $373.56M.
When is Candel Therapeutics, Inc.’s upcoming earnings report date?
Candel Therapeutics, Inc.’s upcoming earnings report date is May 07, 2026 which is in 56 days.
How were Candel Therapeutics, Inc.’s earnings last quarter?
Candel Therapeutics, Inc. released its earnings results on Mar 12, 2026. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.244 by -$0.296.
Is Candel Therapeutics, Inc. overvalued?
According to Wall Street analysts Candel Therapeutics, Inc.’s price is currently Undervalued.
Does Candel Therapeutics, Inc. pay dividends?
Candel Therapeutics, Inc. does not currently pay dividends.
What is Candel Therapeutics, Inc.’s EPS estimate?
Candel Therapeutics, Inc.’s EPS estimate is -0.29.
How many shares outstanding does Candel Therapeutics, Inc. have?
Candel Therapeutics, Inc. has 73,246,925 shares outstanding.
What happened to Candel Therapeutics, Inc.’s price movement after its last earnings report?
Candel Therapeutics, Inc. reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.244. Following the earnings report the stock price went down -6.301%.
Which hedge fund is a major shareholder of Candel Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CADL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Candel Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (194.12% Upside)
$15.00 (194.12% Upside)
Blogger Sentiment
Bullish
CADL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 18.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 11.8%
Last 30 Days ▲ 11.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.32%
12-Months-Change
Fundamentals
Return on Equity
-29.24%
Trailing 12-Months
Asset Growth
335.00%
Trailing 12-Months
Company Description
Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
CADL Stock 12 Month Forecast
Average Price Target
$15.00
▲(194.12% Upside)
Technical Analysis
Tonix Pharma
―
Quantum-Si
―
Humacyte
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
19.77% Insiders
18.07% Mutual Funds
3.04% Other Institutional Investors
51.68% Public Companies and
Individual Investors